Anything above $22.50M is all Dacogen aml sales in EU. Last year at this time they wrote down the AVII invesntment. That was around $2M, so earnings should be good. More drugs in clinics, so expenses should be increasing some. HopefullY Dr. M can give some details on spinoff, if it's still in the cards. Looking forward to this announcement.
Quick look and things look ok from a 2012 standpoint. They lowered the 2013 revenue royalty number again. This time it is $55M vs $60M two weeks ago. Loss for 2013 is up because the tax benefit is projected to be $5M vs previous $8M estimate.
Hope they give some insight on why the royalty rev is down again.
I am still watching and learning, mostly that we keep talking about a drug that was the product of the previous management team.
Where the heck is Phase lll for SEVERAL new compounds? It has been almost 15 years!